[BOLERO -- another remarkable step in treatment of XXXX ].

@entity0 @entity5 @entity1206 @entity2239 @entity17082
The expansion of molecular genetic knowledge leads to targeted therapy which is a common part of @entity5 treatment. Targeted agents also exist for @entity0 . However, new efficient molecules are urgently needed. On one hand, there are @entity5 subgroups where we do not have efficient targeted drugs, on the other hand, the results of established @entity5 therapies can be improved by interfering with another signal transduction pathway. @entity2239 is a targeted agent which was effective in several clinical trials and became registered for treatment of hormone receptor positive @entity0 . This article summarizes the results of @entity0 @entity2239 trials. The results of two phase 3 trials are available. In the BOLERO-2 trial @entity17082 was compared with the combination of @entity17082 and @entity2239 , while in BOLERO-3 trial trastuzumab and @entity1206 were investigated with or without @entity2239 . In both trials the progression-free survival was significantly longer in the experimental arm. The overall survival data of BOLERO-2 trial, a secondary end point, are also available. The 4.4 month benefit in the experimental arm is clinically important but it has not reached the level of statistical significance. We have not had biomarkers so far that could help us to identify a subgroup of @entity5 sensitive to @entity2239 .
